HIV Clinical Pharmacology & Therapeutics Research Training Program

这是一份名为“HIV临床药理学和治疗学研究培训”的D43更新申请 （HIVRT）计划由布法罗大学（UB）和津巴布韦大学（UZ）领导。优化HIV 预防艾滋病毒传播的预防性治疗和预防性治疗（TasP），以满足95-95-95和“结束 疫情”的战略。然而，成功地使用这些方法需要继续进行研究， 指导中低收入国家的实施工作。艾滋病毒治疗将增加 合格的研究人员寻求外部资金为这项研究工作。随着替诺福韦的引入， 拉米夫定和度鲁特韦，长效ARV（例如，cabotegravir，rilpivirine），新的ARV（例如，lenacapavir， islatravir）和HIV-1广泛中和抗体（bNAB），与这些相关的临床和转化研究 需要新的治疗剂来检查最佳药代动力学-药效学参数， 将防止传播和/或维持病毒载量抑制以及在共病情况下的安全性。 临床科学家和转化科学家的培训将利用先前建立的基础， UB-UZ HIVRT和过渡到新设计的研究培训计划。具体目标：1）提供艾滋病毒治疗 为博士前（5）和博士后（5）的学员，增加了独立的研究人员的数量， 资助项目，重点关注艾滋病毒临床药理学和治疗学以及区域公共卫生优先事项 包括COVID-19，2）在团队科学方面指导HIVRT学员，包括其他在以下方面具有专业知识的人： 药物生物分析，生物医学信息学，数据科学，基因组学和微生物组学，3）福斯特 社区支持小组参与创新研究，研究新的艾滋病毒临床 预防和治疗的药理学和治疗学策略，并研究长效 抗逆转录病毒药物、单克隆抗体和传统药物，以及4）提供一种HIVRT， 旨在实现可持续发展目标的学术-公共-私营伙伴关系。学员将有 在UB的强化培训，在此期间，新的知识和技能将允许制定一个研究项目， 将在UZ进行为期18个月的持续监督，总共为期两年的培训。的 该计划将建立在我们之前的福格蒂国际中心艾滋病毒研究培训计划，以及更早的 AITRP。这些研究培训计划为D43更新提供了基础，其中包括 UZ和UB导师的杰出团队，他们将利用HIV临床 药理学和治疗学基础，已建立艾滋病毒临床和转化研究。的 课程将通过一个既定的研究和教育培训核心组织和提供。的 D43有一个出色的外部培训咨询委员会，将有助于建立一个高效、高效的 津巴布韦艾滋病毒临床药理学和治疗研究培训倡议。

This is a renewal application for a D43 titled, HIV Clinical Pharmacology and Therapeutics Research Training (HIVRT) program led by the University at Buffalo (UB) and the University of Zimbabwe (UZ). Optimizing HIV prevention of transmission with HIV PReP and treatment as prevention (TasP) to meet 95-95-95 and “ending the epidemic” strategies. However, successful use of these approaches requires that continued research be conducted to guide implementation in low-middle income countries. The HIVRT will increase the number of qualified investigators to seek external funding for this research effort. With the introduction of tenofovir, lamivudine and dolutegravir, long-acting ARVs (e.g., cabotegravir, rilpivirine), new ARVs (e.g., lenacapavir, islatravir) and HIV-1 broadly neutralizing antibodies (bNABs), clinical and translational research related to these new therapeutic agents is needed to examine the optimal pharmacokinetics-pharmacodynamics parameters that will prevent transmission and/or sustain viral load suppression as well as safety in the context of co-morbidities. Training of clinician-scientists and translational scientists will utilize the foundation that has been built by the prior UB-UZ HIVRT and transition to the newly designed research training program. Specific Aims: 1) Provide a HIVRT for pre-doctoral (5) and post-doctoral (5) trainees that increases the number of researchers with independent, funded programs with a focus on HIV clinical pharmacology and therapeutics and regional public health priorities including COVID-19, 2) Mentor HIVRT trainees in team science and that include others with expertise in pharmaceutical bioanalysis, biomedical informatics, data sciences, genomics, and microbiome, 3) Foster community support group engagement to participate in innovative research to study novel HIV clinical pharmacology and therapeutics strategies for prevention and treatment and investigate long-acting antiretrovirals and monoclonal antibodies and traditional medicines, and 4) Provide an HIVRT that fosters smart academic-public-private partnerships aimed at addressing sustainable developmental goals. Trainees will have intensive training at UB during which new knowledge and skills will allow formulation of a research project that will be conducted under continued supervision for 18 months at UZ for a total of two years of training. The program will build on our prior Fogarty International Center HIV Research Training program, and an earlier AITRP. These research training programs provide the foundation for this D43 renewal that includes an outstanding group of UZ and UB mentors who will provide mentoring and collaboration utilizing the HIV Clinical Pharmacology and Therapeutics foundation that has been built for HIV clinical and translational research. The curriculum will be organized and provided through an established Research and Education Training Core. The D43 has an outstanding external Training Advisory Committee that will contribute to a highly productive, efficient HIV Clinical Pharmacology and Therapeutics research training initiative in Zimbabwe.